Diphencyprone
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Diphencyprone
- DrugBank Accession Number
- DB12173
- Background
Diphencyprone has been used in trials studying the treatment and basic science of Melanoma, Ultraviolet Rays, Immunosuppression, Neoplasm Metastasis, and Hypersensitivity, Delayed, among others.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 206.244
Monoisotopic: 206.073164942 - Chemical Formula
- C15H10O
- Synonyms
- Diphenylcyclopropenone
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Alopecia areata (aa) ••• ••••• •••••••• Treatment of Viral warts ••• ••••• •••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Not Available
- Direct Parent
- Benzene and substituted derivatives
- Alternative Parents
- Cyclic ketones / Organic oxides / Hydrocarbon derivatives
- Substituents
- Aromatic homomonocyclic compound / Cyclic ketone / Hydrocarbon derivative / Monocyclic benzene moiety / Organic oxide / Organic oxygen compound / Organooxygen compound
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- cyclopropenone (CHEBI:53074)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- I7G14NW5EC
- CAS number
- 886-38-4
- InChI Key
- HCIBTBXNLVOFER-UHFFFAOYSA-N
- InChI
- InChI=1S/C15H10O/c16-15-13(11-7-3-1-4-8-11)14(15)12-9-5-2-6-10-12/h1-10H
- IUPAC Name
- diphenylcycloprop-2-en-1-one
- SMILES
- O=C1C(=C1C1=CC=CC=C1)C1=CC=CC=C1
References
- General References
- NCATS Drugs: Diphencyprone [Link]
- External Links
- Human Metabolome Database
- HMDB0251457
- PubChem Compound
- 65057
- PubChem Substance
- 347828461
- ChemSpider
- 58568
- ChEBI
- 53074
- ChEMBL
- CHEMBL1373467
- ZINC
- ZINC000001020197
- Wikipedia
- Diphenylcyclopropenone
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Vitiligo 1 3 Recruiting Treatment Alopecia Areata (AA) 1 1 Active Not Recruiting Treatment Neurofibromas, Cutaneous 1 1 Completed Basic Science Immune Tolerance/Drug Effects / Immunosuppression / Type IV hypersensitivity reaction / Ultraviolet Rays 1 1 Completed Treatment Melanoma / Metastatic Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00987 mg/mL ALOGPS logP 3.72 ALOGPS logP 3.85 Chemaxon logS -4.3 ALOGPS pKa (Strongest Basic) -8.3 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 17.07 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 64.42 m3·mol-1 Chemaxon Polarizability 22.74 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 152.7389137 predictedDarkChem Lite v0.1.0 [M-H]- 152.4907137 predictedDarkChem Lite v0.1.0 [M-H]- 146.73073 predictedDeepCCS 1.0 (2019) [M+H]+ 150.8389137 predictedDarkChem Lite v0.1.0 [M+H]+ 150.7039137 predictedDarkChem Lite v0.1.0 [M+H]+ 149.1263 predictedDeepCCS 1.0 (2019) [M+Na]+ 150.8702137 predictedDarkChem Lite v0.1.0 [M+Na]+ 150.3559137 predictedDarkChem Lite v0.1.0 [M+Na]+ 155.03883 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 21:32 / Updated at December 03, 2022 09:37